Experience in the Design and Production of Recombinant Oral Vaccine «Revax VZT»
Objective of the work was the production of recombinant vaccine «RevaxVZT» in tablet dosage form against hepatitis B and pathogenic for humans orthopoxviruses for further clinical trials. Materials and methods. Recombinant strain b7.5S2-S of vaccinia virus carrying a DNA fragment of hepatitis B viru...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Federal Government Health Institution, Russian Research Anti-Plague Institute “Microbe”
2019-10-01
|
| Series: | Проблемы особо опасных инфекций |
| Subjects: | |
| Online Access: | https://journal.microbe.ru/jour/article/view/1180 |
| _version_ | 1797220809924673536 |
|---|---|
| author | A. I. Terent’ev V. A. Zhukov Ar. A. Sergeev S. B. Pastushenko S. V. Rоgоzhkina S. V. Borisevich V. A. Maksimov Al. A. Sergeev K. A. Titova D. O. Galakhova |
| author_facet | A. I. Terent’ev V. A. Zhukov Ar. A. Sergeev S. B. Pastushenko S. V. Rоgоzhkina S. V. Borisevich V. A. Maksimov Al. A. Sergeev K. A. Titova D. O. Galakhova |
| author_sort | A. I. Terent’ev |
| collection | DOAJ |
| description | Objective of the work was the production of recombinant vaccine «RevaxVZT» in tablet dosage form against hepatitis B and pathogenic for humans orthopoxviruses for further clinical trials. Materials and methods. Recombinant strain b7.5S2-S of vaccinia virus carrying a DNA fragment of hepatitis B virus inserted into thymidinekinase gene was used as an active component of the vaccine. Microbiological, virological, physical, physical and chemical, and biotechnological methods were used for studying the quality of the drug and technological processes. Results and discussion. Results of technological control for semi-finished products and final products of the vaccine “Revax VZT” showed the possibility of using certified hardware-processing line of “TEOVac” for its manufacturing. Same technology can be potentially used with other live tableted embryo smallpox vaccines too. For the development of the vaccine “Revax VZT” with the specific activity of not less than 1.0·107 PFu/tablet, it is necessary to use a dry virus-containing material with activity not less than 2.0·108 PFU/g which is produced by freeze-drying of liquid virus-containing preparation with the activity of not less than 1.0·108 PFU/g, preferentially propagated from chorionic allantoic membranes of chicken embryos as a substrate for viral biomass accumulation. |
| first_indexed | 2024-03-08T13:42:26Z |
| format | Article |
| id | doaj.art-82caec297f4545c59d859c44a9ba1362 |
| institution | Directory Open Access Journal |
| issn | 0370-1069 2658-719X |
| language | Russian |
| last_indexed | 2024-04-24T12:55:27Z |
| publishDate | 2019-10-01 |
| publisher | Federal Government Health Institution, Russian Research Anti-Plague Institute “Microbe” |
| record_format | Article |
| series | Проблемы особо опасных инфекций |
| spelling | doaj.art-82caec297f4545c59d859c44a9ba13622024-04-05T16:47:14ZrusFederal Government Health Institution, Russian Research Anti-Plague Institute “Microbe”Проблемы особо опасных инфекций0370-10692658-719X2019-10-0103949910.21055/0370-1069-2019-3-94-991140Experience in the Design and Production of Recombinant Oral Vaccine «Revax VZT»A. I. Terent’ev0V. A. Zhukov1Ar. A. Sergeev2S. B. Pastushenko3S. V. Rоgоzhkina4S. V. Borisevich5V. A. Maksimov6Al. A. Sergeev7K. A. Titova8D. O. Galakhova948th Central Research Institute of the Ministry of Defense of the Russian Federation48th Central Research Institute of the Ministry of Defense of the Russian FederationState Scientific Center of Virology and Biotechnology «Vector»48th Central Research Institute of the Ministry of Defense of the Russian Federation48th Central Research Institute of the Ministry of Defense of the Russian Federation48th Central Research Institute of the Ministry of Defense of the Russian Federation48th Central Research Institute of the Ministry of Defense of the Russian FederationState Scientific Center of Virology and Biotechnology «Vector»State Scientific Center of Virology and Biotechnology «Vector»State Scientific Center of Virology and Biotechnology «Vector»Objective of the work was the production of recombinant vaccine «RevaxVZT» in tablet dosage form against hepatitis B and pathogenic for humans orthopoxviruses for further clinical trials. Materials and methods. Recombinant strain b7.5S2-S of vaccinia virus carrying a DNA fragment of hepatitis B virus inserted into thymidinekinase gene was used as an active component of the vaccine. Microbiological, virological, physical, physical and chemical, and biotechnological methods were used for studying the quality of the drug and technological processes. Results and discussion. Results of technological control for semi-finished products and final products of the vaccine “Revax VZT” showed the possibility of using certified hardware-processing line of “TEOVac” for its manufacturing. Same technology can be potentially used with other live tableted embryo smallpox vaccines too. For the development of the vaccine “Revax VZT” with the specific activity of not less than 1.0·107 PFu/tablet, it is necessary to use a dry virus-containing material with activity not less than 2.0·108 PFU/g which is produced by freeze-drying of liquid virus-containing preparation with the activity of not less than 1.0·108 PFU/g, preferentially propagated from chorionic allantoic membranes of chicken embryos as a substrate for viral biomass accumulation.https://journal.microbe.ru/jour/article/view/1180recombinant strain of vaccinia virushepatitis вorthopoxviruses pathogenic for humanssmallpox vaccine in tabletstechnologyhardware-processing line |
| spellingShingle | A. I. Terent’ev V. A. Zhukov Ar. A. Sergeev S. B. Pastushenko S. V. Rоgоzhkina S. V. Borisevich V. A. Maksimov Al. A. Sergeev K. A. Titova D. O. Galakhova Experience in the Design and Production of Recombinant Oral Vaccine «Revax VZT» Проблемы особо опасных инфекций recombinant strain of vaccinia virus hepatitis в orthopoxviruses pathogenic for humans smallpox vaccine in tablets technology hardware-processing line |
| title | Experience in the Design and Production of Recombinant Oral Vaccine «Revax VZT» |
| title_full | Experience in the Design and Production of Recombinant Oral Vaccine «Revax VZT» |
| title_fullStr | Experience in the Design and Production of Recombinant Oral Vaccine «Revax VZT» |
| title_full_unstemmed | Experience in the Design and Production of Recombinant Oral Vaccine «Revax VZT» |
| title_short | Experience in the Design and Production of Recombinant Oral Vaccine «Revax VZT» |
| title_sort | experience in the design and production of recombinant oral vaccine revax vzt |
| topic | recombinant strain of vaccinia virus hepatitis в orthopoxviruses pathogenic for humans smallpox vaccine in tablets technology hardware-processing line |
| url | https://journal.microbe.ru/jour/article/view/1180 |
| work_keys_str_mv | AT aiterentev experienceinthedesignandproductionofrecombinantoralvaccinerevaxvzt AT vazhukov experienceinthedesignandproductionofrecombinantoralvaccinerevaxvzt AT arasergeev experienceinthedesignandproductionofrecombinantoralvaccinerevaxvzt AT sbpastushenko experienceinthedesignandproductionofrecombinantoralvaccinerevaxvzt AT svrogozhkina experienceinthedesignandproductionofrecombinantoralvaccinerevaxvzt AT svborisevich experienceinthedesignandproductionofrecombinantoralvaccinerevaxvzt AT vamaksimov experienceinthedesignandproductionofrecombinantoralvaccinerevaxvzt AT alasergeev experienceinthedesignandproductionofrecombinantoralvaccinerevaxvzt AT katitova experienceinthedesignandproductionofrecombinantoralvaccinerevaxvzt AT dogalakhova experienceinthedesignandproductionofrecombinantoralvaccinerevaxvzt |